NASDAQ: SLNOSoleno Therapeutics Inc Stock
$43.11-1.41 (-3.17%)
Updated Jan 10, 2025
SLNO Price
$43.11
Fair Value Price
$10.26
Market Cap
$1.86B
52 Week Low
$36.61
52 Week High
$60.92
P/E
-15.97x
P/B
7.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$131.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$51M
Beta
0.64
Next Earnings
Mar 4, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SLNO Overview
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SLNO's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Value
D
Growth
C
Momentum
F
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SLNO
Ranked#535 of 556
Ranked#535 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.25 | A | |
| $121.41 | A | |
| $5.27 | A |
Be the first to know about important SLNO news, forecast changes, insider trades & much more!
SLNO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLNO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLNO ($43.11) is overvalued by 320% relative to our estimate of its Fair Value price of $10.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLNO ($43.11) is not significantly undervalued (320%) relative to our estimate of its Fair Value price of $10.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLNO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLNO due diligence checks available for Premium users.
Valuation
SLNO fair value
Fair Value of SLNO stock based on Discounted Cash Flow (DCF)
Price
$43.11
Fair Value
$10.26
Overvalued by
320.00%
SLNO ($43.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLNO ($43.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLNO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLNO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.97x
Industry
-113.93x
Market
30.06x
SLNO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.02x
Industry
4.88x
SLNO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLNO's financial health
Profit margin
Revenue
$0.0
Net Income
-$76.6M
Profit Margin
0%
SLNO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$296.7M
Liabilities
$32.0M
Debt to equity
0.12
SLNO's short-term assets ($258.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLNO's short-term assets ($258.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLNO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SLNO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.9M
Investing
$4.0M
Financing
$2.3M
SLNO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLNO vs Biotech Stocks
Soleno Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.